Peace of Mind.

The future of neuroimaging is here.

Peace of Mind.

The future of neuroimaging analysis is here and Qynapse is leading the way. For clinicians on the front lines, for patients and their families, for payers, and for pharma – we offer peace of mind by providing results you can trust.

Combining MRI scans and artificial intelligence to produce rapid, actionable insights into central nervous system (CNS) disorders.

On the front lines of neuroscience, imaging for diagnosis and prognosis of central nervous system (CNS) diseases like Alzheimer’s, Multiple Sclerosis and Parkinson’s has reached new heights. However, in too many cases, neuroimaging leaves more questions than answers.

When health practitioners, patients and caregivers have a more accurate and reliable diagnosis of CNS disease, timely interventions and lifestyle changes are more successful and patient outcomes can dramatically improve. And when pharmaceutical companies have a higher probability of success in clinical trials, their potentially life-changing therapies can make an impact sooner.

The Qynapse neuroscience team, with the support and guidance of CNS disease experts around the world, is wholly dedicated to aspiring to build tools and software that analyze brain images and other markers of neurodegeneration to create the clearest, most accurate and reliable predictors and objective measures of CNS disorders.

On the front lines of neuroscience, imaging for diagnosis and prognosis of central nervous system (CNS) diseases like Alzheimer’s, Multiple Sclerosis and Parkinson’s has reached new heights. However, in too many cases, neuroimaging leaves more questions than answers.

When health practitioners, patients and caregivers have a more accurate and reliable diagnosis of CNS disease, timely interventions and lifestyle changes are more successful and patient outcomes can dramatically improve. And when pharmaceutical companies have a higher probability of success in clinical trials, their potentially life-changing therapies can make an impact sooner.

The Qynapse neuroscience team, with the support and guidance of CNS disease experts around the world, is wholly dedicated to aspiring to build tools
and software that analyze brain images and other markers of neurodegeneration to create the clearest, most accurate and reliable predictors and objective measures of CNS disorders.

%

Misdiagnosis Rate

The current rate of misdiagnosis in CNS disease ranges up to 30%.

Automated Measures

Of neuroinflammation and neurodegeneration

Normative Dataset

Largest normative dataset of over 10,000 brain scan images

Advanced Technology

16 global patents
and 20 algorithms

How we get there.

QyScore® produces a wide range of automated neuroimaging biomarkers to assist physicians making clinical care decisions and monitoring patients over time. QyScore® is FDA-Cleared, CE-Marked and soon expanding into new global markets.

 

QyScore® also has demonstrated superior performance compared to certain other automated state-of-the-art methods and has been validated against gold-standard manual segmentation.

AI-powered and proprietary neuroimaging software platform, QyScore®, aims to provide physicians, pharma researchers and payers an objective layer of precision when making a CNS disease diagnosis. QyPredict®, for research use only, is being designed to transform what we know about CNS disease
trajectory by combining genomics, biofluids, neuroimaging, cognitive endpoints and measures of activities of daily living to help guide health decisions.

 

Qyscore® is a medical device software FDA-cleared – class II and CE-marked – class IIa (CE BSI). 

Indications for Use in the U.S. (FDA): QyScore® is intended for automatic labeling, visualization and volumetric quantification of segmentable brain structures and lesions from a set of MR images. Volumetric data may be compared to reference percentile data. QyScore® is not intended for use in clinical scenarios that require evaluation of the number of the white matter hyperintensities.

Indications for Use in Europe (CE): QyScore® is an advanced processing and visualization software for automatic labeling and volumetric quantification of segmented central nervous system structures for patients older than 18 years of age. The software is intended to be used by medical personnel or neuroimaging trained personnel to support diagnosis of central nervous system diseases.